TSX:ONC 0.92 CAD -0.02 -2.13% Volume: 44,747 April 1, 2015
NASDAQ:ONCY 0.73 USD -0.01 -1.35% Volume: 570,553 April 1, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

March 26, 2015 Oncolytics Biotech® Inc. Presents at the 2015 Immune Checkpoint Inhibitors Meeting
March 25, 2015 Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Ovarian Cancer
March 16, 2015 Oncolytics Biotech® Inc. Announces 2014 Year End Results
Sign up to receive e-mail updates *